Thus, with the knowledge that the clinical effects of decreasing C1Q activity in human HD is under active investigation with ANX005, an antibody targeting C1Q, and with the increasing characterization of the role of microglia in HD pathogenesis, we sought to investigate the impact of deletion of Tyrobp in the HD Q175 mouse model. Here, TYROBP is linked to Huntington disease.